Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States

The seroprevalence of HSV-2 has declined, particularly in younger Americans.

What's known?

  • HSV type 1 and 2 can cause either anogenital or oropharyngeal infection.
  • HSV-1 has become an increasingly common cause of clinical anogenital herpes in developed countries.
  • Pre-existing HSV-1 antibodies can alleviate clinical manifestations of subsequently acquired HSV-2.

What’s new?

  • Cross-sectional, nationally representative surveys (US National Health and Nutrition Examination Surveys [NHANES], were used to compare national HSV seroprevalence estimates from 1999-2004 with those from 1988-1994.
  • The analyses included 9165 persons from 1988-1994 survey and 11508 persons from 1999-2004 survey who were aged 14 to 49 years.
  • The overall age-adjusted HSV-2 seroprevalence was 17.0% in 1999-2004 and 21.0% in 1988-1994, a relative decrease of 19.0% between the 2 surveys (95% CI, –28.6% to –9.5%; P<.001).
  • The decrease in HSV-2 seroprevalence was concentrated in younger age groups.
  • Overall decrease was greater in males (31.9%) than in females (19.4%).
  • Among those infected with HSV-2, the percentage who reported having been diagnosed with genital herpes was statistically different (14.3% in 1999-2004 and 9.9% in 1988-1994; P = .02).
  • Seroprevalence of HSV-1 decreased from 62.0 in 1988-1994 to 57.7% in 1999-2004, a relative decrease of 6.9% between the 2 surveys (95% CI, –11.6% to –2.3%; P = .006).
  • Among persons infected with HSV-1 but not with HSV-2, a higher percentage reported having been diagnosed with genital herpes in 1999-2004 compared with 1988-1994 (1.8% vs 0.4%, respectively; P<.001).
  • The authors have suggested that the reasons for significant decrease in HSV-2 seroprevalence even after accounting for changes in measured sexual behaviour may include factors such as careful partner selection, condom use and or choosing oral sex over vaginal sex.
  • The changing HSV-1 seroprevalence may also have an impact on genital herpes as declines in HSV acquisition before onset of sexual activity will leave more individuals susceptible to genitally acquired HSV-1 infection when they become sexually active. Also, more individuals will acquire HSV-2 without HSV-1 antibodies. Confirmation of HSV type may contribute to optimal management of patients with symptomatic genital herpes.
Research summary
Author(s): 

Fujie Xu, Maya R. Sternberg, Benny J. Kottiri, Geraldine M. McQuillan, Francis K. Lee, Andre J. Nahmias, Stuart M. Berman, Lauri E. Markowitz

Full title: 

Trends in Herpes Simplex Virus Type 1 and Type 2 Seroprevalence in the United States.

Publication details: 

JAMA; 296:964–973.

Abstract: 

Context: Herpes simplex virus type 1 (HSV-1) and type 2 are common infections worldwide. Herpes simplex virus type 2 (HSV-2) is the cause of most genital herpes and is almost always sexually transmitted. In contrast, HSV-1 is usually transmitted during childhood via nonsexual contacts. Preexisting HSV-1 antibodies can alleviate clinical manifestations of subsequently acquired HSV-2. Furthermore, HSV-1 has become an important cause of genital herpes in some developed countries.

Objective: To examine trends in HSV-1 and HSV-2 seroprevalence in the United States in 1999-2004 compared with 1988-1994.

Design, Settings, and Participants: Cross-sectional, nationally representative surveys (US National Health and Nutrition Examination Surveys [NHANES]), were used to compare national seroprevalence estimates from 1999-2004 with those from 1988-1994, and changes in HSV-1 and HSV-2 seroprevalence since 1976-1980 were reviewed. Persons aged 14 to 49 years were included in these analyses.

Main Outcome Measures: Seroprevalence of HSV-1 and HSV-2 antibodies based on results from type-specific immunodot assays; diagnosis of genital herpes.

Results: The overall age-adjusted HSV-2 seroprevalence was 17.0% (95% confidence interval [CI], 15.8%-18.3%) in 1999-2004 and 21.0% (95% CI, 19.1%-23.1%) in 1988-1994, a relative decrease of 19.0% between the 2 surveys (95% CI, –28.6% to –9.5%; P<.001). Decreases in HSV-2 seroprevalence were especially concentrated in persons aged 14 to 19 years between 1988 and 2004. In adolescents aged 17 to 19 years and young adults, the decreases in HSV-2 seroprevalence were significant even after adjusting for changes in sexual behaviors. Among those infected with HSV-2, the percentage who reported having been diagnosed with genital herpes was statistically different (14.3% in 1999-2004 and 9.9% in 1988-1994; P = .02). Seroprevalence of HSV-1 decreased from 62.0% (95% CI, 59.6%-64.6%) in 1988-1994 to 57.7% (95% CI, 55.9%-59.5%) in 1999-2004, a relative decrease of 6.9% between the 2 surveys (95% CI, –11.6% to –2.3%; P = .006). Among persons infected with HSV-1 but not with HSV-2, a higher percentage reported having been diagnosed with genital herpes in 1999-2004 compared with 1988-1994 (1.8% vs 0.4%, respectively; P<.001).

Conclusions: These data show declines in HSV-2 seroprevalence, suggesting that the trajectory of increasing HSV-2 seroprevalence in the United States has been reversed. Seroprevalence of HSV-1 decreased but the incidence of genital herpes caused by HSV-1 may be increasing.

More information

Australian Herpes Management Forum, c/- STIRC, Marian Villa, Westmead Hospital, Westmead NSW 2145, Australia.

Telephone: +61 (2) 8230 3843 - Fax: +61 (2) 9845 6287

Contact AHMF by email - ACN 096 346 477 - ABN 85 096 346 477